Education
About Us
Working with TipRanks
Follow Us
Opus Genetics (IRD)
NASDAQ:IRD
IRD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.71 - $2.18
Previous CloseN/A
Volume154.21K
Average Volume (3M)246.44K
Market Cap
$35.86M
Enterprise Value$26.09M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)0.00
Price to Earnings (P/E)―
Beta0.61
Next Earnings
May 09, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.99
Shares Outstanding47,183,823
10 Day Avg. Volume197,802
30 Day Avg. Volume246,443
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.75
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.00Price Target Upside952.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsInitial positive visual acuity gains have been observed in patients with advanced LCA5 disease, indicating potential for clinical advancement.
Regulatory ProspectsRegulators seem open to novel endpoints, which bodes well for OPGx-LCA5 regulatory prospects.
Strategic PartnershipsThe partnership for phentolamine ophthalmic solution, funded by Viatris, adds diversity to the company’s pipeline and offers multiple upcoming data catalysts.
Bears Say
Investor SentimentSome investors believe that a new therapy will need to show significant vision improvement (and not just prevention of worsening) to garner adoption.
---
Ownership Overview
9.47% Insiders
4.15% Mutual Funds
10.12% Other Institutional Investors
72.89% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
IRD FAQ
What was Opus Genetics’s price range in the past 12 months?
Opus Genetics lowest stock price was $0.71 and its highest was $2.18 in the past 12 months.
What is Opus Genetics’s market cap?
Opus Genetics’s market cap is $35.86M.
When is Opus Genetics’s upcoming earnings report date?
Opus Genetics’s upcoming earnings report date is May 09, 2025 which is in 28 days.
How were Opus Genetics’s earnings last quarter?
Opus Genetics released its earnings results on Mar 06, 2025. The company reported -$1.27 earnings per share for the quarter, missing the consensus estimate of -$0.245 by -$1.025.
Is Opus Genetics overvalued?
According to Wall Street analysts Opus Genetics’s price is currently Undervalued.
Does Opus Genetics pay dividends?
Opus Genetics does not currently pay dividends.
What is Opus Genetics’s EPS estimate?
Opus Genetics’s EPS estimate is -0.29.
How many shares outstanding does Opus Genetics have?
Opus Genetics has 47,183,823 shares outstanding.
What happened to Opus Genetics’s price movement after its last earnings report?
Opus Genetics reported an EPS of -$1.27 in its last earnings report, missing expectations of -$0.245. Following the earnings report the stock price went up 1.01%.
Which hedge fund is a major shareholder of Opus Genetics?
Currently, no hedge funds are holding shares in IRD
---
Opus Genetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (952.63% Upside)
$8.00 (952.63% Upside)
Blogger Sentiment
Bullish
IRD Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $97.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.13%
12-Months-Change
Fundamentals
Return on Equity
-203.19%
Trailing 12-Months
Asset Growth
-31.62%
Trailing 12-Months
Company Description
Opus Genetics
Opus Genetics is a biotechnology company focused on developing gene therapies for inherited retinal diseases (IRDs). The company operates within the pharmaceutical and biotechnology sectors, leveraging cutting-edge gene-editing technologies to address unmet medical needs in the field of ocular diseases. Opus Genetics aims to restore vision and improve the quality of life for patients suffering from rare genetic eye disorders.
---
IRD Stock 12 Month Forecast
Average Price Target
$8.00
▲(952.63% Upside)
Technical Analysis
Best Analysts Covering IRD
1 Year
1 Year Success Rate
6/22 ratings generated profit
1 Year Average Return
-10.73%
reiterated a buy rating 10 days ago
Copying Matthew Caufield's trades and holding each position for 1 Year would result in 27.27% of your transactions generating a profit, with an average return of -10.73% per trade.
---